FEDERALhearing transcript

Congressional Hearing on Substance Use During the Pandemic

Original title: AN EPIDEMIC WITHIN A PANDEMIC: UNDERSTANDING SUBSTANCE USE AND MISUSE IN AMERICA

January 1, 2022

substance abuse public health COVID-19 drug policy mental health

Track this bill to get notified when it advances a stage. One tap to stop, anytime.

The Frame

What this does

The hearing serves as a formal record of federal legislative inquiry into how pandemic-related conditions impacted national substance use trends and informs future federal policy and funding priorities regarding addiction services.

Who is mentioned in the record

Potentially affected actors named in the source documents. Mention is not a position.

White House Office of National Drug Control Policy

The agency is responsible for coordinating federal drug control policy and provided testimony regarding their current efforts.

Substance use treatment providers

The hearing discussed policies and trends that impact the delivery and funding of addiction treatment services.

What changed

Last recorded activity January 1, 2022.

What's next

Next step not available in the current record.

Summary

This document is the official record of a virtual hearing held by the House on April 14, 2021. The hearing examined the intersection of the COVID-19 pandemic and the ongoing crisis of substance use and misuse in the United States.

Key Facts

The hearing was held virtually on April 14, 2021.
The hearing was titled 'An Epidemic Within a Pandemic: Understanding Substance Use and Misuse in America'.
The hearing was conducted by the Subcommittee on Health of the Committee on Energy and Commerce.
Regina M. LaBelle, Acting Director of the White House Office of National Drug Control Policy, provided testimony.
Geoffrey Laredo, Principal of Santa Cruz Strategies, LLC, provided testimony.
The document includes opening statements from Representatives Anna G. Eshoo, Brett Guthrie, Frank Pallone, Jr., and Cathy McMorris Rodgers.
The hearing record includes prepared statements and answers to submitted questions from witnesses.

Frequently Asked Questions

What was the purpose of this hearing?

The hearing was held to understand the impact of the COVID-19 pandemic on substance use and misuse in the United States.

Who testified at this hearing?

The witnesses were Regina M. LaBelle, Acting Director of the White House Office of National Drug Control Policy, and Geoffrey Laredo, Principal of Santa Cruz Strategies, LLC.

Why It Matters

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Discoveries

Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.

policy shift90% confidence

Pandemic-era focus

The hearing explicitly frames substance abuse as an 'epidemic within a pandemic,' highlighting the shift in focus toward how COVID-19 restrictions and stressors impacted addiction rates.

House Subcommittee on Health

Connected Entities

personRegina M. LaBelle“Acting Director, White House Office of National Drug Control Policy”Map →

organizationHouse Subcommittee on Health“Committee conducting the hearing”Map →

organizationCommittee on Energy and Commerce“Parent committee of the Subcommittee on Health”Map →

personBrett Guthrie“Ranking Member of the Subcommittee on Health”Map →

personGeoffrey Laredo“Principal, Santa Cruz Strategies, LLC”Map →

personAnna G. Eshoo“Chairwoman of the Subcommittee on Health”Map →

Sources

Open source document

www.govinfo.gov

Analysis Score

0–100

Significance60
How much this matters to a regular citizen
Controversy20
Intensity of disagreement among stakeholders
Entertainment5
Compellingness for a non-policy-wonk reader
Buzz10
Current news / social attention level

Publisher tools